Cargando…
Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293444/ https://www.ncbi.nlm.nih.gov/pubmed/28151881 http://dx.doi.org/10.1097/MD.0000000000005944 |
_version_ | 1782505082926923776 |
---|---|
author | Cui, Zhigang Liu, Dezhong Liu, Chun Liu, Gang |
author_facet | Cui, Zhigang Liu, Dezhong Liu, Chun Liu, Gang |
author_sort | Cui, Zhigang |
collection | PubMed |
description | Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies suitable for further investigation. A meta-analysis was conducted on these studies to investigate the association between serum selenium levels and subsequent prostate cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the overall OR of prostate cancer for the highest versus the lowest levels of serum selenium. We found a pooled OR (95% CI) of 0.76 (0.64, 0.91; P < 0.05). In subgroup analysis, an inverse association between serum selenium levels and prostate cancer risk was found in each of case–control studies, current and former smokers, high-grade cancer cases, advanced cancer cases, and different populations. Such correlations were not found for subgroups containing each of cohort studies, nonsmokers, low-grade cancer cases, and early stage cancer cases. In conclusion, our study suggests an inverse relationship between serum selenium levels and prostate cancer risk. However, further cohort studies and randomized control trials based on non-Western populations are required. |
format | Online Article Text |
id | pubmed-5293444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-52934442017-02-10 Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis Cui, Zhigang Liu, Dezhong Liu, Chun Liu, Gang Medicine (Baltimore) 7300 Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies suitable for further investigation. A meta-analysis was conducted on these studies to investigate the association between serum selenium levels and subsequent prostate cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the overall OR of prostate cancer for the highest versus the lowest levels of serum selenium. We found a pooled OR (95% CI) of 0.76 (0.64, 0.91; P < 0.05). In subgroup analysis, an inverse association between serum selenium levels and prostate cancer risk was found in each of case–control studies, current and former smokers, high-grade cancer cases, advanced cancer cases, and different populations. Such correlations were not found for subgroups containing each of cohort studies, nonsmokers, low-grade cancer cases, and early stage cancer cases. In conclusion, our study suggests an inverse relationship between serum selenium levels and prostate cancer risk. However, further cohort studies and randomized control trials based on non-Western populations are required. Wolters Kluwer Health 2017-02-03 /pmc/articles/PMC5293444/ /pubmed/28151881 http://dx.doi.org/10.1097/MD.0000000000005944 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 7300 Cui, Zhigang Liu, Dezhong Liu, Chun Liu, Gang Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title | Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title_full | Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title_fullStr | Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title_full_unstemmed | Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title_short | Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis |
title_sort | serum selenium levels and prostate cancer risk: a moose-compliant meta-analysis |
topic | 7300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293444/ https://www.ncbi.nlm.nih.gov/pubmed/28151881 http://dx.doi.org/10.1097/MD.0000000000005944 |
work_keys_str_mv | AT cuizhigang serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis AT liudezhong serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis AT liuchun serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis AT liugang serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis |